Karyopharm Therapeutics Inc - Discuss Selinexor As A Potential Treatment For Hospitalized Patients With COVID-19 Transcript
Good morning. My name is Cherie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics COVID-19 Clinical Trial Initiation Conference Call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Mr. Ian Karp, Karyopharm's Vice President, Investor and Public Relations.
Thank you, Cherie, and thank you all for joining us on today's conference call to discuss the initiation of a new clinical trial to evaluate low-dose selinexor as a potential treatment for hospitalized patients with COVID-19. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, our Chief Executive Officer; Dr. Sharon Shacham, President and Chief Scientific Officer; and Dr. Jatin Shah, Chief Medical Officer.
On the call today, Dr. Kauffman will provide a brief overview of the scientific rationale for our new clinical
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |